Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

New agents for inhibiting EGF receptor-mediated abnormal cell growth

June 25, 1998

More telomerase inhibitors added to the Geron pipeline

June 25, 1998

Potent angiogenesis inhibitor AG-3340 profiled at NCI-EORTC symposium

June 24, 1998

Introgen Therapeutics acquires exclusive option to license PTEN gene

June 24, 1998

Phase II evaluation of carzelesin in NHL

June 24, 1998

Miproxifene phosphate, a promising treatment for breast cancer

June 24, 1998

Management strategy including hydroxyurea successful in unresectable meningioma

June 24, 1998

S-16020-2: a topoisomerase II inhibitor selective for renal cancers heads for phase II testing

June 24, 1998

Select Therapeutics signs agreement for cancer vaccine platform technology

June 24, 1998

Lilly presents results of first clinical trial evaluating the MDR modulator LY-335979

June 23, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...